Genetic and molecular mechanism of intrathecal morphine induced itch in patients with advanced tumors

Not Applicable

• Conditions: drug induced pruritus

• Registration Number: ChiCTR2400088773
• Lead Sponsor: Zhongshan Hospital Affiliated to Fudan University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1)Voluntary participation, patients themselves understand and sign the informed consent form;<br>2)Age: 18-80 years old; <br>3)Tumor etiology; <br>4)Recent vital signs maintained relatively stable, clear and answerable; <br>5)The patient has no previous history of pruritus-related medical conditions,and no symptoms of pruritus for other routes of administration of opioids; <br>6)Bilirubin-related biochemical indicators in the normative range; <br>7)Voluntary morphine pump implantation surgery, no contraindication to morphine pump implantation.

Exclusion Criteria

1. Pruritus history is relevant: previous skin disease, chronic urticaria, chemotherapy-associated pruritus and erythema, cholestatic pruritus, diabetic pruritus, itchy manifestations of opioids administered by oral, intravenous, and subcutaneous routes; <br>2) Morphine pump implantation is contraindicated: hypocoagulability (abnormal coagulation function or platelet <75×10^9 /L); hemodynamic instability, sepsis, intracranial hypertension, spinal cord tuberculosis, cerebrospinal fluid outflow and other spinal cord-related diseases and tumors close to the site of puncture and other inappropriate implantation conditions; <br>3) Complications of morphine pump implantation: bleeding, infection, catheter tip dislocation, tip granuloma formation, etc; <br>4)Combination of psychological disorders, severe neurosis, pregnancy, etc; <br>5)patients with a history of combined gout, rheumatoid diseases, bile duct and pancreatic diseases;<br>6)recent allergic events; <br>7)patients who received allogeneic blood transfusion in the last month; <br>8) patients with lack of expression or impairment of voluntary movement of limbs.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sequencing of the opioid receptor MOR;

Secondary Outcome Measures

Name	Time	Method
Itching, pain scale scores;